Extracorporeal photopheresis in the treatment of chronic graft-versus-host disease. The Hellenic experience: A study by the Hellenic association of hematology

作者：Tsirigotis Panagiotis^*; Kaloyannidis Panayotis; Papalexandri Apostolia; Baltadakis Ioannis; Karakasis Dimitrios; Batsis Ioannis; Sakellari Ioanna; Kitra Vassiliki; Goussetis Evgenios; Papageorgiou Sotirios; Spyridonidis Alexandros; Graphakos Stelios; Harhalakis Nikolaos; Dervenoulas Ioannis; Anagnostopoulos Achilles

来源：Transfusion and Apheresis Science, 2012, 46(2): 173-180.

DOI：10.1016/j.transci.2011.09.001

• Graft-versus-host disease
• Extracorporeal photopheresis
• Relapse
• Steroid refractory

The Hellenic experience regarding the efficacy of extracorporeal photopheresis (ECP) in the treatment of 58 patients with chronic graft-versus-host disease (cGVHD) is presented in this article. All 58, except one patient, had failed at least one line of immunosuppressive treatment including steroids. %26lt;br%26gt;Thirty-three out of 58 patients showed an objective overall response to ECP in a median time of 10 weeks after the onset of treatment. The cumulative incidence of overall response was 65.1%. In multivariate analysis, the presence of severe chronic GVHD was the only parameter associated with a significantly lower probability of response to treatment (RR = 0.4, CI 95% 0.2-0.9, p = 0.03). Responders to treatment with ECP were more likely to discontinue immunosuppression, had a lower probability of non-relapse mortality (RR = 0.2, CI 95% 0.1-0.5, p = 0.002), and a higher probability of overall survival (RR = 7.8, CI 95% 3-20, p %26lt; 0.001) in comparison with non-responders. Eight out of 58 patients experienced relapse of the original disease. The cumulative incidence of relapse in the group of responders to ECP was 6%, while it was 25% in the group of non-responders to ECP. In multivariate analysis, response to treatment with ECP was the only parameter statistically associated with a significantly decreased hazard of relapse (RR = 0.1, CI 95% 0.1-0.7, p = 0.02). ECP should be tested as first-line treatment in patients with cGVHD with the aim to minimize the duration of immunosuppression and the rate of relapse of the malignant disease.

• 出版日期2012-4